Skip to main content
. 2023 Jul 26;17:1582. doi: 10.3332/ecancer.2023.1582

Table 3. Performance parameters of 99mTc-EDDA/HYNIC-TOC and 111In-DTPA-OCTREOTIDE.

(A) Any image (B) Liver-specific images (C) Whole-body images
99mTc 111In p 99mTc 111In p 99mTc 111In p
Sensitivity 93.7%
(88.1 – 96.8)
74.8%
(66.6 – 81.6)
< 0.001 97.8%
(92.7 – 99.5)
85.1%
(76.6 – 91.0)
< 0.001 77.1 (61.1 – 88.1) 45.7% (30.4 – 61.7) NS*
Specificity 50% (15.0 – 84.9) 50% (15.0 – 84.9) 0.61 75% (41.5 – 93.4) 75% (41.5 – 93.4) 0.61 71.4 (36.4 – 92.3) 71.4% (36.4 – 92.3)
Positive LR 1.49 (0.88 – 4.52) 1.87 (1.11 – 5.64) 0.75 3.91 (1.61 – 10.90) 3.40 (1.4 – 10.17) 0.84 2.7 (1.13 – 8.52) 1.6 (0.62 – 5.56) NS*
Negative LR 0.50 (0.28 – 1.55) 0.12 (0.05 – 0.42) 0.08 0.02 (0.009 – 0.1) 0.19 (0.12 – 0.42) 0.009 0.32 (0.16 – 0.78) 0.76 (0.52 – 1.61)
*

When the global Wald test was not significant, individual comparisons were not performed and thus are not presented

99mTc: 99mTc -EDDA/HYNIC-TOC; 111In: 111In -DTPA-OCTREOTIDE; LR: Likelihood Ratio; PV: Predictive Value; NS: Not Significant

Estimated sensitivities, specificities, and LRs of 99mTc-EDDA/HYNIC-TOC and 111In-DTPA-OCTREOTIDE according to disease detection in (A) Any images, (B) Liver-specific images and (C) Whole-body images